Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) and Ovid Therapeutics (NASDAQ:OVID – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, earnings, dividends, profitability, valuation and risk.
Profitability
This table compares Milestone Pharmaceuticals and Ovid Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Milestone Pharmaceuticals | N/A | -288.33% | -58.27% |
| Ovid Therapeutics | N/A | -23.64% | -20.52% |
Volatility and Risk
Milestone Pharmaceuticals has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500.
Institutional and Insider Ownership
86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 5.0% of Milestone Pharmaceuticals shares are held by insiders. Comparatively, 7.0% of Ovid Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Milestone Pharmaceuticals and Ovid Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Milestone Pharmaceuticals | $2.34 million | 34.44 | -$63.06 million | ($0.69) | -0.94 |
| Ovid Therapeutics | $1.58 million | 266.48 | -$17.41 million | ($0.31) | -6.97 |
Ovid Therapeutics has lower revenue, but higher earnings than Milestone Pharmaceuticals. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Milestone Pharmaceuticals and Ovid Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Milestone Pharmaceuticals | 1 | 1 | 4 | 1 | 2.71 |
| Ovid Therapeutics | 1 | 0 | 11 | 1 | 2.92 |
Milestone Pharmaceuticals currently has a consensus target price of $6.40, indicating a potential upside of 887.35%. Ovid Therapeutics has a consensus target price of $6.00, indicating a potential upside of 177.78%. Given Milestone Pharmaceuticals’ higher possible upside, equities analysts clearly believe Milestone Pharmaceuticals is more favorable than Ovid Therapeutics.
Summary
Ovid Therapeutics beats Milestone Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
About Ovid Therapeutics
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
